Prostate cancer will become an epidemic male health problem due to increasing life expectancy. There is a critical need for accurate imaging evaluation of patients with metastatic prostate cancer. Positron emission tomography (PET) with the most common tracer currently available, [F-18]-fluorodeoxyglucose (FDG), has emerged as an important diagnostic imaging modality in cancer. Recent advances in imaging technology have also resulted in dual-modality PET-CT systems that allow precise fusion of anatomic and metabolic imaging data. Our preliminary in-vitro cell culture, animal in-vivo, and pilot clinical studies have provided compelling evidence that FDG PET may have a significant role in the imaging evaluation of patients with metastatic prostate cancer. There are two specific aims for this research proposal: 1) to assess the diagnostic utility of FDG PET-CT in the evaluation of therapy response in two clinically distinct groups of patients with metastatic prostate cancer, Group I: men with newly diagnosed hormone-naive metastatic disease who will be treated with the standard androgen ablation therapy, and Group II: men with newly developed hormone-refractory metastatic cancer who will be treated with standard chemotherapy, and 2) to evaluate FDG PET-CT in predicting patient outcome. We hypothesize that semi-quantitative FDG PET-CT monitoring of the serial changes in the glucose metabolism of metastatic prostate cancer lesions provides a competitive advantage over the conventional methods in the objective assessment of treatment response and in predicting key clinical outcomes. To test this hypothesis, we will perform a prospective cohort study to evaluate the diagnostic and prognostic utility of serial FDG PET-CT imaging in determining tumor metabolic response to either androgen ablation therapy or to chemotherapy and in predicting key clinical outcomes such as time to hormone-refractory state and survival. Rigorous statistical methods will be applied to determine the diagnostic and prognostic performance of FDG PET-CT in this clinical setting. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA111613-01A1
Application #
6982959
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Shankar, Lalitha K
Project Start
2005-08-12
Project End
2010-05-31
Budget Start
2005-08-12
Budget End
2006-05-31
Support Year
1
Fiscal Year
2005
Total Cost
$496,349
Indirect Cost
Name
University of Southern California
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Jadvar, Hossein; Chen, Xiaoyuan; Cai, Weibo et al. (2018) Radiotheranostics in Cancer Diagnosis and Management. Radiology 286:388-400
Chau, Albert; Gardiner, Peter; Colletti, Patrick M et al. (2018) Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases. Clin Nucl Med 43:e226-e231
Jadvar, Hossein (2017) Highlights of articles published in annals of nuclear medicine 2016. Eur J Nucl Med Mol Imaging 44:1928-1933
Jadvar, Hossein; Park, Ryan; Yap, Li-Peng et al. (2017) Effect of Androgen on Normal Biodistribution of [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice. Anticancer Res 37:475-479
Jadvar, Hossein (2017) Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer. Clin Transl Imaging 5:199-208
Jadvar, Hossein (2017) Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol 209:277-288
Jadvar, Hossein (2016) Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer. Abdom Radiol (NY) 41:889-98
Iagaru, Andrei H; Mittra, Erik; Colletti, Patrick M et al. (2016) Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. J Nucl Med 57:19S-24S
Jadvar, Hossein (2016) Radiotheranostics in Prostate Cancer: Introduction and Overview. J Nucl Med 57:1S-2S
Jadvar, Hossein (2016) Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med 46:502-506

Showing the most recent 10 out of 43 publications